Results 161 to 170 of about 17,654,627 (326)
Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling
Molecular Oncology, EarlyView.AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu +5 morewiley +1 more sourcePARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer +21 morewiley +1 more sourceCharacterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane +9 morewiley +1 more sourceBridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular Oncology, EarlyView.Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme +8 morewiley +1 more sourceSecond international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine
Nature Medicine, 2023 Deirdre K. Tobias, Jordi Merino, Abrar Ahmad, Catherine E Aiken, Jamie L. Benham, D. Bodhini, Amy L. Clark, K. Colclough, Rosa Corcoy, S. Cromer, D. Duan, Jamie L. Felton, E. C. Francis, P. Gillard, Véronique Gingras, R. Gaillard, Eram Haider, A. Hughes, Jennifer M. Ikle, Laura M. Jacobsen, A. Kahkoska, J. Kettunen, R. Kreienkamp, Lee-Ling Lim, Jonna M E Männistö, Robert Massey, N. Mclennan, Rachel G. Miller, M. Morieri, J. Most, Rochelle N Naylor, Bige Ozkan, K. Patel, Scott J. Pilla, Katsiaryna Prystupa, Sridharan Raghavan, M. Rooney, M. Schön, Zhila Semnani-Azad, Magdalena Sevilla-González, Pernille Svalastoga, W. Takele, C. H. Tam, A. Thuesen, Mustafa Tosur, Amelia S. Wallace, Caroline C. Wang, Jessie J. Wong, Jennifer M. Yamamoto, K. Young, Chloé Amouyal, M. K. Andersen, M. Bonham, Mingling Chen, Feifei Cheng, T. Chikowore, Sian C. Chivers, Christoffer Clemmensen, Dana Dabelea, A. Dawed, A. Deutsch, L. Dickens, L. Dimeglio, Monika Dudenhöffer-Pfeifer, C. Evans-Molina, M. Fernández-Balsells, H. Fitipaldi, Stephanie L Fitzpatrick, S. Gitelman, M. Goodarzi, J. Grieger, M. Guasch-Ferré, Nahal Habibi, T. Hansen, Chuiguo Huang, A. Harris-Kawano, H. M. Ismail, Benjamin Hoag, Randi K. Johnson, A. Jones, R. Koivula, Aaron Leong, Gloria K. W. Leung, I. Libman, Kai Liu, S. A. Long, W. Lowe, Robert W Morton, A. Motala, Suna Onengut-Gumuscu, J. Pankow, Maleesa M. Pathirana, S. Pazmino, Dianna Perez, John R. Petrie, Camille E. Powe, Alejandra Quinteros, Rashmi Jain, D. Ray, M. Ried-Larsen, Zeb I. Saeed, V. Santhakumar, Sarah Kanbour, Sudipa Sarkar, G. Monaco, D. Scholtens, E. Selvin, Wayne Huey-Herng Sheu, C. Speake, M. Stanislawski, N. Steenackers, A. Steck, Norbert Stefan, Julie Støy, Rachael Taylor, Sok Cin Tye, G. G. Ukke, Marzhan Urazbayeva, Bart Van der Schueren, C. Vatier, J. Wentworth, Wesley Hannah, Sara L. White, Gechang Yu, Yingchai Zhang, Shao J. Zhou, J. Beltrand, Michel Polak, I. Aukrust, E. De Franco, Sarah E. Flanagan, Kristin A. Maloney, Andrew P McGovern, J. Molnes, M. Nakabuye, P. Njølstad, Hugo Pomares-Millan, Michele Provenzano, C. Saint-Martin, Cuilin Zhang, Yeyi Zhu, S. Auh, Russell J de Souza, Andrea J. Fawcett, Chandra Gruber, E. G. Mekonnen, Emily Mixter, D. Sherifali, Robert H. Eckel, J. Nolan, L. Philipson, Rebecca J. Brown, L. Billings, Kristen E. Boyle, T. Costacou, J. Dennis, J. C. Florez, A. Gloyn, M. Gomez, Peter A. Gottlieb, S. Greeley, Kurt J. Griffin, A. Hattersley, Irl B. Hirsch, M. Hivert, Korey K. Hood, Jami L. Josefson, S. Kwak, L. Laffel, Siew Lim, Ruth J. F. Loos, R. Ma, Chantal Mathieu, N. Mathioudakis, J. Meigs, S. Misra, Viswanathan Mohan, R. Murphy, Richard A. Oram, K. Owen, S. Ozanne, E. Pearson, W. Perng, T. Pollin, R. Pop-Busui, R. Pratley, L. Redman, M. J. Redondo, Rebecca M. Reynolds, Robert K. Semple, J. Sherr, E. Sims, A. Sweeting, T. Tuomi, M. Udler, K. Vesco, Tina Vilsbøll, R. Wagner, S. Rich, P. Franks +199 moresemanticscholar +1 more sourceAdenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer
Molecular Oncology, EarlyView.A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski +14 morewiley +1 more sourceInvestigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer
Molecular Oncology, EarlyView.This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov +10 morewiley +1 more sourceIntegrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer
Molecular Oncology, EarlyView.A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar +13 morewiley +1 more source
